UCB SA

ENXTBR:UCB 株式レポート

時価総額：€45.9b

UCB マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Jean-Christophe Tellier

最高経営責任者

€12.4m

報酬総額

CEO給与比率11.26%
CEO在任期間11.3yrs
CEOの所有権n/a
経営陣の平均在職期間5.8yrs
取締役会の平均在任期間8.6yrs

経営陣の近況

Recent updates

ナラティブの更新 • May 15

UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential

Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
ナラティブの更新 • Apr 30

UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside

The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.
ナラティブの更新 • Apr 16

UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile

Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.
ナラティブの更新 • Apr 01

UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance

Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.
ナラティブの更新 • Mar 18

UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance

The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
ナラティブの更新 • Mar 04

UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price

We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.
ナラティブの更新 • Feb 18

UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance

Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.
ナラティブの更新 • Feb 04

UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution

Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.
ナラティブの更新 • Jan 21

UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential

Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.
ナラティブの更新 • Jan 07

UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise

Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.
ナラティブの更新 • Dec 18

UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside

UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.
ナラティブの更新 • Dec 04

UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential

UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.
ナラティブの更新 • Nov 20

UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher

Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.
分析記事 • Nov 11

UCB (EBR:UCB) Could Easily Take On More Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
ナラティブの更新 • Nov 06

UCB: Strong Profit Margins And Momentum Will Drive Shares Higher

UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.
ナラティブの更新 • Oct 22

Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts

UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.
分析記事 • Oct 14

Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher

UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...
ナラティブの更新 • Oct 08

Aging Populations And Emerging Markets Will Unlock Opportunity

UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.
ナラティブの更新 • Sep 24

Aging Populations And Emerging Markets Will Unlock Opportunity

The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.
ナラティブの更新 • Aug 27

Aging Populations And Emerging Markets Will Unlock Opportunity

Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.
分析記事 • Jul 17

UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
User avatar
新しいナラティブ • Mar 02

BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology

UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.

CEO報酬分析

UCB の収益と比較して、Jean-Christophe Tellier の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2025€12m€1m

€2b

Sep 30 2025n/an/a

€1b

Jun 30 2025n/an/a

€1b

Mar 31 2025n/an/a

€1b

Dec 31 2024€7m€1m

€1b

Sep 30 2024n/an/a

€653m

Jun 30 2024n/an/a

€240m

Mar 31 2024n/an/a

€292m

Dec 31 2023€7m€1m

€343m

Jun 30 2023n/an/a

€332m

Mar 31 2023n/an/a

€376m

Dec 31 2022€6m€1m

€420m

Jun 30 2022n/an/a

€887m

Mar 31 2022n/an/a

€971m

Dec 31 2021€6m€1m

€1b

Sep 30 2021n/an/a

€996m

Jun 30 2021n/an/a

€936m

Mar 31 2021n/an/a

€834m

Dec 31 2020€7m€1m

€732m

Jun 30 2020n/an/a

€743m

Mar 31 2020n/an/a

€767m

Dec 31 2019€87kn/a

€790m

報酬と市場: Jean-Christopheの 総報酬 ($USD 14.45M ) は、 Belgian市場 ($USD 2.86M ) の同規模の企業の平均を上回っています。

報酬と収益: Jean-Christopheの報酬は過去 1 年間で 20% 以上増加しました。

CEO

Jean-Christophe Tellier (66 yo)

11.3yrs
在職期間
€12,434,367
報酬

Dr. Jean-Christophe Tellier is Chief Executive Officer of UCB Ventures S.A. Dr. Jean-Christophe Tellier is CEO & Executive Director of UCB SA from July 01, 2020. Dr. Tellier served as Executive Vice Presid...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jean-Christophe Tellier
CEO & Executive Director11.3yrs€12.43mデータなし
Sandrine Dufour
Executive VP & CFO5.8yrsデータなしデータなし
Alistair Henry
Executive VP & Chief Scientific Officer2yrsデータなしデータなし
Denelle J. Johnson
Executive VP & General Counsel3.1yrsデータなしデータなし
Jean-Luc Fleurial
Executive VP & Chief Human Resources Officer6.3yrsデータなしデータなし
Emmanuel Caeymaex
Executive Vice President of Patient Evidence11.3yrsデータなしデータなし
Kirsten Lund-Jurgensen
Executive Vice President of Patient Supply2.3yrsデータなしデータなし
Fiona du Monceau
Executive VP of Patient Impact & Chief Commercial Officer2.1yrsデータなしデータなし
Caroline Vancoillie
Chief Accounting Officer & Head of Group Finance13.2yrsデータなしデータなし
Gwendoline Ornigg
Head of Global Corporate Communicationno dataデータなしデータなし
Veronique Toully
Head of Sustainabilityno dataデータなしデータなし
Martin Citron
VP & Head of Neuroscience TA New Medicinesno dataデータなしデータなし
5.8yrs
平均在職期間
58.5yo
平均年齢

経験豊富な経営陣: UCBの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。

取締役

名称ポジション在職期間報酬所有権
Jean-Christophe Tellier
CEO & Executive Director12.1yrs€12.43mデータなし
Gerhard Mayr
Honorary Chairmanno data€70.00kデータなし
Mark Eyskens
Honorary Chairman21.3yrs€15.50kデータなし
Daniel Janssen
Honorary Deputy Chairmanno data€28.50kデータなし
Georges Jacobs Hagen
Honorary Chairmanno data€30.00kデータなし
Diégo du de Bergendal
Honorary Chairman5.1yrs€87.50kデータなし
Karel Boone
Honorary Chairmanno data€49.00kデータなし
Judy L. Brown
Independent Directorless than a yearデータなしデータなし
Jonathan Peacock
Independent Chair of the Board5.1yrs€438.33kデータなし
Charles-Antoine Janssen
Vice-Chair of the Board14.1yrs€192.33kデータなし
Nefertiti Greene
Independent Director2.3yrs€197.33kデータなし
Jonkheer van Rijckevorsel
Director12.1yrs€157.83kデータなし
8.6yrs
平均在職期間
67yo
平均年齢

経験豊富なボード: UCBの 取締役会 は 経験豊富 であると考えられます ( 8.6年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 12:10
終値2026/05/21 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

UCB SA 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。40

アナリスト機関
Charles PitmanBarclays
Brian BourdotBarclays
Charles PitmanBarclays